


SERVICIO DE ENDOCRINOLOGÍA Y NUTRICIÓN



Fecha CV: 06/10/2023

Pablo Valderrábano Herrero

*Facultativo Especialista en Endocrinología y Nutrición.
Doctor en Medicina por la Universidad de Autónoma de Madrid.
Unidad de Cáncer de Tiroides
Consulta Monográfica de Cáncer de Tiroides y Consulta de alta
resolución de nódulos tiroideos.
Áreas de interés: Cáncer de tiroides y nódulos tiroideos*

BIOGRAPHICAL SKETCH			
NAME: Pablo Valderrábano Herrero. BIRTH DATE & LOCATION: November 25 th , 1982, Zaragoza, Spain		POSITION TITLE: Medical Consultant in Endocrinology and Nutrition	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Universidad de Zaragoza	M.D.	2006	Medicine & Surgery
Hospital Universitario Puerta de Hierro Majadahonda	Specialist	2011	Endocrinology & Nutrition
Universidad de Autónoma de Madrid	Ph.D.	2017	Medicine & Surgery

A. Positions and Honors.

Positions and Employment

2007-2011	Medical Residency, Endocrinology & Nutrition, Hospital Universitario Puerta de Hierro Majadahonda, Madrid (Spain)
2011-2013	Medical Consultant in Endocrinology and Nutrition in Madrid area (Spain)
2014-2016	Clinical Research Fellow. Department of Head and Neck, and Endocrine Oncology. H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL).
2016-2018	Postdoctoral Fellow. Department of Head and Neck, and Endocrine Oncology. H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL).
2018-present	Medical Consultant in Endocrinology and Nutrition, Thyroid Cancer Unit, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid (Spain)

Other Experience and Professional Memberships

- Memberships: Spanish Society of Endocrinology and Nutrition (2008-present); Spanish Diabetes Society (2009-present); Society of Endocrinology, Nutrition and Diabetes of the Community of Madrid (2010-present); American Association of Clinical Endocrinologists (2014-2018); American Thyroid Association (2014-present); Endocrine Society (2014-2018). European Thyroid Association (2022-present)

Awards and Honors

- 2005 **Research Collaboration Grant of the Science and Educational Ministry of Spain.** Human Anatomy and Histopathology Department, Zaragoza University. "Caracterización de canales iónicos por inmunocitoquímica en neuronas de *Helix aspersa* sometidas a exposición a campo magnético"
- 2007 **Position number 235 of 9579 applicants in the MIR exam** (Spanish national exam to access the residency programs).
- 2011 **SENDIMAD 2011 Award to the best "Clinical Communication"** of the 10th Annual Meeting of the Endocrinology, Diabetes and Nutrition Society of Madrid. Aranjuez, Spain. Project: "Are the New Glycemic Criteria for the Diagnosis of Gestational Diabetes Mellitus Appropriate in our Population?"
- 2014 **Sponsored 2-year Clinical Research Fellowship at Moffitt Cancer Center awarded by the Alfonso Martín Escudero Foundation (Spain).** Project: "Diagnóstico diferencial de cáncer de tiroides: evitando cirugías". Total Amount of Award: € 70,000.

- 2015 **2015 International Thyroid Congress Trainee Grant** awarded by the International Thyroid Congress Committee; **2015 AACE Young Investigator Poster Presentation Award, First Place.** For the poster: "Sonographic pattern stratifies the risk of malignancy of thyroid nodules with indeterminate cytology."; **2015 AACE Travel Grant Winner**, selected by the Abstract Review Subcommittee based upon merit and significance to the science and practice of endocrinology (1 of 5 travel grants for domestic Fellow-in-Training).
- 2016 **Junior Scientist Partnership Award:** Award for collaborative projects that bridge clinical and basic science trainees and/or early-stage clinical researchers. Project: "Individualizing the indeterminate thyroid nodules' malignancy risk through artificial neural networks"; **2016 ATA Trainee Grant** awarded by the American Thyroid Association.
- 2017 **2017 ATA Trainee Grant** awarded by the American Thyroid Association.
- 2020 **Winner of the 4th Healthstart madri+d program** awarded by Fundación Madrimasd para el conocimiento (Madrid). Proyecto: "Cuantificación inteligente de la imagen ecográfica para mejorar la fiabilidad diagnóstica."
- 2021 **IV Best publication Award SENDIMAD 2021**, Award to the best article published in scientific journals by groups established in Madrid, awarded by SENDIMAD. Publication: "Outcomes of repeat fine needle aspiration biopsy for AUS/FLUS thyroid nodules." *European Journal of Endocrinology*. 185 - 4, pp. 497 - 506.

B. Publication record (03/2022):

B.1. h index: 16 (WOS). Q1 publications: 15. ORCID: 0000-0001-8379-2709

B.2. Selected peer-reviewed publications (1st author or senior)

1. *Evaluation of Thyroid Ultrasound Reports' Quality in the Community of Madrid, Spain. European Thyroid Journal*. 2025; 14(1):e240390
2. *Appropriate and mindful measurement of serum calcitonin in patients with thyroid nodules. A white paper. Endocrine*. 2024; 83-1:60-64.
3. *Clinical value of molecular markers as diagnostic and prognostic tools to guide treatment of thyroid cancer. Clin Endocrinol (Oxf)*. 2023; 98(6):753-762
4. *Evaluation of Body Composition in Patients With and Without Adrenal Tumors and Without Overt Hypersecretory Syndromes. Endocr Pract*. 2023; 29(2):110-118
5. *Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas. Hormones (Athens)*. 2023; 22(1): 51-59
6. *Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study. Clin Endocrinol (Oxf)*. 2023; 98(2):165-176
7. *A Proposal for Nomenclature Revision of Nonfunctioning Adrenal Incidentalomas as Adrenal Lesions of Undetermined Secretion of Adrenal Steroids (ALUSAS). Endocr Pract*. 2022; 28(9): 918-920
8. *Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours. Sci Rep*. 2022; 12(1):2671.
9. *Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas. J Clin Med*. 2021; 10(23):5509
10. *Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion. Sci Rep*. 2021; 11(1):20539
11. *Outcomes of repeat fine needle aspiration biopsy for AUS/FLUS thyroid nodules. Eur J Endocrinol*. 2021; 185(4):497-506.
12. *Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas. Hormones (Athens)*. 2021; 20(4): 753-744.
13. *Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas. J Endocrinol Invest*. 2021; 44(11):2349-2357
14. *Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid*. 2021; 31(1):36-49.
15. *Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations. Thyroid*. 2020; 30(8):1132-140.
16. *Comparison of Postmarketing Findings vs the Initial Clinical Validation Findings of a Thyroid Nodule Gene Expression Classifier: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg*. 2019; 145(9): 783 -792.
17. *Cytologically indeterminate thyroid nodules: Impact of size on histological and clinical outcomes. JAMA Otolaryngol Head Neck Surg*. 2018; 144(9):788-95.
18. *Thyroid nodules with indeterminate cytology: Utility of ATA sonographic patterns for cancer risk stratification. Thyroid*. 2018; 28(8):1004-12.
19. *Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules. Head Neck*. 2018; 40(8): 1812-23.
20. *Cancer risk associated with nuclear atypia in cytologically indeterminate thyroid nodules: A systematic review and meta-analysis. Thyroid*. 2018; 28(2):210-219.
21. *Evaluation and management of indeterminate thyroid nodules: the revolution of risk stratification beyond cytological diagnosis. Cancer Control*. 2017; 24(5): 1073274817729231.
22. *Cancer risk stratification of indeterminate thyroid nodules: A cytological approach. Thyroid*. 2017; 27(10):1277-84.
23. *Evaluation of ThyroSeq v2 Performance in Thyroid Nodules with Indeterminate Cytology. Endocr Relat Cancer*. 2017;

- 24(3):127-136.
24. *Hypermetabolism on 18F-FDG PET scan does not influence the interpretation of thyroid cytopathology and nodules with SUVmax <2.5 are not at increased risk for malignancy.* Thyroid. 2016; 26(9):1300-1307.
 25. *The new ATA sonographic patterns for thyroid nodules perform well in medullary thyroid carcinoma: Institutional experience, systematic review and meta-analysis.* Thyroid. 2016; 26(8):1093-100.
 26. *Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests.* Eur J Endocrinol. 2016; 174(5):621-9.
 27. *Molecular assays in cytopathology for thyroid cancer.* Cancer Control. 2015; 22(2): 152-157.
 28. *Results of repeat transsphenoidal surgery in Cushing's disease. Long term follow-up.* Endocrinol Nutr. 2014; 61(4):176-83.

C. Research Support Role: selected grants as Principal & Contributor Researcher

1. Title: PI23/01626, Aplicaciones ULISSES para el análisis e informe inteligentes de ecografía tiroidea y mamaria (U-START). **Name of PI: Pablo Valderrabano.** Study number: PI23/01626. Funding source: ISCIII - AES 2023, Proyectos de Investigación en Salud/FEDER. Total Amount of Award: 140.000 €. Dates: 01/01/2024-31/12/2026.
2. Title: Mejora de la reconstrucción volumétrica de nódulos tiroideos usando aparatología ultrasónica dedicada basada en posicionadores inerciales. **Name of PI: Pablo Valderrabano** & Carlos Julián Martín Arguedas. Study number: UAH-IRYCIS23/08. Funding Source: IRYCIS/UAH. Total Amount of Award: **12.000€.** Dates: 22/12/2023-21/12/2024.
3. Title: Estudio de la heterogeneidad celular y del entorno inmunológico en las patologías tiroideas: cáncer y enfermedad autoinmune (ITIRONET-CM). **Name of consortium coordinator: Mercedes Robledo Batanero.** IRYCIS Project name: Estudio de la toxicidad hematológica del tratamiento con [131I]NaI (I-CHIP: Radioactive Iodine-induced Clonal Hematopoiesis of Indeterminate Potential). **Name of IRYCIS PI: Pablo Valderrabano.** Funding Source: Comunidad de Madrid. Total Amount of Award: **921.000 €.** Dates: 01/01/2023-31/12/2026.
4. Title: Optimización de proceso de reconstrucción volumétrica de nódulos tiroideos a partir de imágenes ecográficas. **Name of PI: Pablo Valderrabano** & Carlos Julián Martín Arguedas. Study number: UAH-IRYCIS 22/09. Funding Source: IRYCIS/UAH. Total Amount of Award: **10.500€.** Dates: 23/12/2022-22/12/2023.
5. Title: Evaluación del Uso y Percepción del Balance Riesgo-Beneficio del Tratamiento con [131I]NaI en España. **Name of PI: Pablo Valderrabano.** Study number: THY-RyC-06. Funding Source: Ramón y Cajal University Hospital. Dates: 12/2021-12/2022
6. Title: Optimización de la calidad de los informes de ecografía tiroidea en la Comunidad de Madrid. **Name of PI: Pablo Valderrabano.** Study number: IPI/2021/N2. Funding Source: SENDIMAD. Total Amount of Award: **10.000€.** Dates: 01/01/2022-31/12/2023
7. Title: Clinical validation of Ultrasound Linearization-based Imaging Smart Solutions and Evaluation Software (ULISSES) for the diagnosis and follow-up of thyroid nodules **Name of PI: Pablo Valderrabano.** Study number: PI20/01177. Funding source: ISCIII - AES 2020, Proyectos de Investigación en Salud/FEDER. Total Amount of Award: **56.870€.** Dates: 01/01/2021 - 31/12/2023
8. Title: ULISSES-BAT: Ultrasound Linearization-based Imaging Smart Solutions and Evaluation Software for Breast And Thyroid nodules' diagnosis. **Name of PI: Pablo Valderrabano.** Study number: THY-RyC-04. Funding source: FUNDACION CIENTIFICA ASOCIACION ESPAÑOLA CONTRA EL CANCER. Total Amount of Award: **180.000€.** Dates: 1/12/2020-31/3/2023
9. Title: Clinical Validation of a 10-gene Thyroid Genetic Classifier for indeterminate thyroid cytology. **Name of site PI: Pablo Valderrabano.** Study number: THY-RyC-03. Funding source: Corporación de Fomento de la Producción de Chile (Corfo) – Agencia estatal de Chile. Dates: 02/2020-present
10. Title: Vallidation study of has-miR-139-5p as prognostic biomarker in thyroid cancer patients. **Name of PI: Pablo Valderrabano.** Study number: THY-RyC-02. Funding source: Hereditary Endocrine Cancer Group of the National Center for Oncologic Research, PI14/00240. Dates: April 2019-present
11. Title: Cuantificación inteligente dela imagen ecográfica para mejorar la fiabilidad diagnóstica. **Name of PI: Pablo Valderrabano.** Funding source: Healthstart madri+d program of the Fundación Madrimasd para el conocimiento. Total Amount of Award: **12.000€.** Dates: 06/2019-03/2020.
12. Title: Multidisciplinary retrospective study of patients with thyroid nodules and thyroid cancer at Ramón y Cajal University Hospital. **Name of PI: Pablo Valderrabano.** Study number: THY-RyC-01. Funding Source: Ramón y Cajal University Hospital. Dates: February 2019-present
13. Title: "Adaptive tyrosine kinase inhibitor therapy in patients with advanced progressive thyroid cancer". Name of PI: Christine H. Chung. Role in the Study: Co-investigator. Study number: MCC 19442. Funding Source: Moffitt Cancer Center Physical Sciences-Oncology Center (PSOC). Total Amount of Award: **\$200,000.** Dates: May 2018-April 2022
14. Title: "Precision medicine for thyroid nodules with indeterminate cytology". Name of PI: Christine H. Chung. Role in the Study: Postdoctoral fellow (% Effort: 30%). Study number: covered under MCC 17728. Funding Source: Moffitt Cancer Center and Research Institute. 2017 Moffitt Team Science Award. Total Amount of Award: **\$100,000.** Dates: April 2018-January 2019
15. Title: "Quantitative Echogenicity assessment of thyroid nodules: A prospective pilot study". Name of PI: Cesar A. Lam. Role in the Study: **Co-PI** (% Effort: 10%). Study number: MCC #19592. Funding Source: Diagnostic Imaging Department, Moffitt Cancer Center and Research Institute. Total Amount of Award: \$20,000. Dates: January-June 2018
16. Title: Retrospective Analysis of Thyroid Cancer Incidence Trends. Name of PI: Julie Hallanger-Johnson. Role in the Study: Co-investigator. Study number: MCC#19459. Funding Source: Moffitt Cancer Center and Research Institute. Dates: January-June 2018

17. Title: Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules. Name of PI: Bryan McIver. Role in the study: Co-investigator. Study number: MCC #18585. Funding source: GeneproDx. Dates: July 2016-June-2018
18. Title: Impact of Ancillary Techniques in the Pre-surgical Diagnosis of Thyroid Nodules. Name of PI: Bryan McIver. Role in the study: Co-investigator. Study number: MCC #18062. Funding source: Moffitt Cancer Center and Research Institute. Dates: June 2015-June 2018
19. Title: Management of Thyroid Nodules and Thyroid Cancer at Moffitt Cancer Center. **Name of PI: Pablo Valderrabano.** Study number: MCC #17728. Funding Source: Moffitt Cancer Center and Research Institute. Dates: January 2014-June 2018.
20. Title: Individualizing the Indeterminate Thyroid Nodules' Malignancy Risk Through Artificial Neural Networks. **Name of PI: Pablo Valderrabano.** Study number: covered under MCC #17728. Funding source: Moffitt Cancer Center and Research Institute. Total Amount of Award: **\$5,000.** Dates: November 1st 2016-October 31st 2017

D. Good Clinical Practices (GCPs) training:

1. CITI Good Clinical Practice Course (Stage 2-Refresher Course). Course completion date: 13-Mar-2018
2. CITI Conflicts of Interest. Course completion date: 12-Aug-2016
3. Biomedical Investigators and Key Personnel (stage 2-Refresher Course). Course completion date: 02-Feb-2016
4. CITI Good Clinical Practice (Basic Course_Moffitt Cancer Center). Course completion date: 02-Feb-2016
5. Human Subjects Research (Basic/Refresher Course). Course completion date: 28-Jan-2016
6. Biomedical Investigators and Key Personnel. Course completion date: 05-Feb-2014
7. Biomedical Responsible Conduct of Research. Course completion date: 05-Feb-2014
8. Biomedical Research (Basic Course). Course completion date: 04-Feb-2014
9. CITI Conflicts of Interest. Course completion date: 04-Feb-2014
10. CITI Good Clinical Practice Course (Basic Course_USF). Course completion date: 04-Feb-2014
11. CITI Good Clinical Practice Course (Basic Course_Moffitt Cancer Center). Course completion date: 03-Feb-2014
12. CITI Health Information Privacy and Security (HIPS) for Clinical Investigators. Course completion date: 31-Jan-2014